Hong Kong-based Uni-Bio Science has secured approval from the China National Medical Products Administration (NMPA) for Bogutai (teriparatide), a treatment for osteoporosis.
Originally developed by Eli Lilly (NYSE: LLY) and marketed as Forteo, teriparatide is a parathyroid hormone (PTH) analog that works by stimulating bone formation in both men and women.
Other generic teriparatide products have also been developed, with a recent US approval being granted for a version manufactured by South Carolina-based Ambio, launched subsequently by Floridian partner Apotex.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze